Glenmark Pharmaceuticals Ltd (GLEN.NS)
18 Aug 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|46||2011||Executive Chairman of the Board, Chief Executive Officer, Managing Director|
|2016||President, Chief Financial Officer|
|2017||Compliance Officer, Company Secretary|
|2017||Executive Director - Global General Counsel, Executive Director|
- BRIEF-Glenmark Pharmaceuticals gets ANDA approval for acyclovir ointment USP, 5 pct
- BRIEF-Glenmark Pharmaceuticals reports positive data in phase 2A study of GBR 830 for treatment of patients with atopic dermatitis
- BRIEF-India's Glenmark Pharmaceuticals June qtr consol profit up about 47 pct
- BRIEF-Glenmark Pharmaceuticals gets ANDA approval for Desonide cream
- BRIEF-Glenmark pharmaceuticals enters exclusive agreement with Cyndea Pharma S.L.